McLaughlin P, Cabanillas F, Hagemeister F B, Velasquez W S
Cancer Treat Rep. 1987 Jun;71(6):631-3.
A total of 50 evaluable adult patients with relapsing lymphoma and two with Hodgkin's disease received bisantrene by central iv catheter every 3 weeks, at doses of 350 mg/m2 for patients with adequate marrow reserve and 300 mg/m2 for those with compromised marrow reserve. The overall response rate was 30% for 50 patients with malignant lymphoma, including seven complete remissions (14%) and eight partial remissions (16%). Neither patient with Hodgkin's disease responded. The 16 patients with follicular lymphomas did particularly well, with 31% attaining complete remission and 25% attaining partial remission. Five of seven complete responders remain in remission at 16-24+ months; two have relapsed, at 13 and 20 months. Leukopenia, of brief duration, was the most common toxic effect. Fever during neutropenia occurred in 23% of courses. There was minimal cardiotoxicity with cumulative doses of up to 7080 mg/m2 of bisantrene. Bisantrene is an effective and well-tolerated agent for the treatment of malignant lymphoma.
共有50例可评估的复发性淋巴瘤成年患者和2例霍奇金病患者，每3周通过中心静脉导管接受比生群治疗，骨髓储备充足的患者剂量为350mg/m²，骨髓储备受损的患者剂量为300mg/m²。50例恶性淋巴瘤患者的总缓解率为30%，包括7例完全缓解（14%）和8例部分缓解（16%）。2例霍奇金病患者均无反应。16例滤泡性淋巴瘤患者疗效特别好，31%达到完全缓解，25%达到部分缓解。7例完全缓解者中有5例在16至24个多月时仍处于缓解状态；2例分别在13个月和20个月时复发。持续时间较短的白细胞减少是最常见的毒性作用。23%的疗程中出现中性粒细胞减少期间发热。比生群累积剂量高达7080mg/m²时心脏毒性极小。比生群是治疗恶性淋巴瘤的一种有效且耐受性良好的药物。
